POZ - Treatment News : What's New? Update on Experimental Agents

Most Talked About
	Magic Johnson Accused of Faking HIV (42) World AIDS Day: Your Feedback (22) Guidelines Prediction: Start Treatment Earlier (blog) (19) My First Facebook Demo (blog) (18) Bone Marrow Transplant: Potential AIDS Cure? (9) Obama Campaign Set to Boost Domestic HIV/AIDS Funding (8)

Most Popular Lessons
	The HIV Life Cycle Herpes Simplex Virus Human Papilloma Virus (HPV) Shingles Syphilis & Neurosyphilis Treatments for Opportunistic Infections (OIs)

More Treatment News

December 2008

November 2008

October 2008

September 2008

August 2008

July 2008

June 2008

May 2008

April 2008

March 2008

February 2008

January 2008

December 2007

November 2007

October 2007

September 2007

August 2007

July 2007

June 2007

May 2007

April 2007

March 2007

February 2007

January 2007

December 2006

November 2006

October 2006

September 2006

August 2006

July 2006

June 2006

May 2006

April 2006

February 2006

March 8, 2007

What's New? Update on Experimental Agents

AIDSmeds founder Peter Staley interviewed Dr. Calvin Cohen, research director of the Community Research Initiative of New England, about new drugs in the pipeline that might help treatment-experienced patients needing new options. Hear the latest news about Isentress and elvitegravir, two integrase inhibitor, maraviroc, a CCR5 inhibitor, and TMC-278, a new non-nuke.

Double click for the full interview (14 minutes):

Or hear part I about Isentress, Merck's new integrase inhibitor (4 minutes):

Or hear part II about elvitegravir, Gilead's new integrase inhibitor (2 minutes):

Or hear part III about maraviroc, Pfizer's new CCR5 inhibitor (5 minutes):

Or hear part IV about TMC-278, Tibotec's new non-nuke (3 minutes):

Or click here to read the full transcript of the interview.

Our post-CROI conference interviews were generously sponsored by Abbott Laboratories.